⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL29157102 | 0.88 | GAA (0.31) | — | |
| SCHEMBL588633 | 0.75 | — | — | |
| SCHEMBL123657 | 0.75 | — | — | |
| SCHEMBL31539802 | 0.74 | — | — | |
| SCHEMBL29737981 | 0.74 | — | — | |
| SCHEMBL1400779 | 0.74 | — | — | |
| SCHEMBL30503583 | 0.74 | — | — | |
| SCHEMBL17285647 | 0.74 | — | — | |
| SCHEMBL403868 | 0.74 | — | — | |
| SCHEMBL411439 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| US-12378223-B2 | Process for preparation of triaminopyrimidine compound and intermediates thereof | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-08-05 | — | — | US | disclosed |
| US-12275728-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-13 | — | — | US | disclosed |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-01-14 | — | — | US | disclosed |
| US-12180205-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240308995-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2024-09-19 | — | — | US | disclosed |
| CN-113166137-B | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranoside enzyme inhibitors | 比奥根MA公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024156938-A1 | CBL-B INHIBITORS | ORION CORPORATION (FI) | 2024-08-02 | — | — | WO | disclosed |
| WO-2010117979-A2 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117979-A2 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-4898608-A | Pyridylthio-acylanilide herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1990-02-06 | — | — | US | disclosed |
| EP-0243868-A2 | Pyridylthio-acylanilides | BAYER AG (DE) | 1987-11-04 | — | — | EP | disclosed |